Regulatory T cells (Tregs) are key mediators of immune tolerance and feature prominently in
cancer. Depletion of CD25+ FoxP3+ Tregs in vivo may promote T cell cancer …

CD4+ regulatory T cells frustrate productive tumor immune surveillance and represent an
obstacle for cancer immunotherapy. In mice, anti‐CD25 antibody is an effective method of …

Intratumoral regulatory T (Treg) cell abundance associates with diminished antitumor
immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the …

Cancers express tumor-associated antigens that should elicit immune response to
antagonize the tumor growth, but spontaneous immune rejection of established cancer is …

Cancer immunotherapy involving blockade of immune checkpoint molecules, such as CTLA‐
4 and PD‐1, has shown remarkable clinical success across several types of malignancies …

CD4+ CD25+ FOXP3+ regulatory T cells (Tregs) are elevated in cancers and can thwart
protective antitumor immunity. Recent human cancer trials suggest that depleting Tregs can …

Highlights•The vital role of FOXP3+ CD25+ CD4+ regulatory T (Treg) cells in tumor immunity
is described.•FOXP3+ CD25+ CD4+ Treg cells are abundantly present in tumor tissues and …

Regulatory T (Treg) cells contribute to immune homeostasis but suppress immune
responses to cancer. Strategies to disrupt Treg cell–mediated cancer immunosuppression …

CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a
target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited …

Regulatory T (Treg) cells suppress abnormal/excessive immune responses to self‐and
nonself‐antigens to maintain immune homeostasis. In tumor immunity, Treg cells are …